According to a recent report filed at the SEC (Securities & Exchange Commission), Moderna, Inc. (NASDAQ: MRNA) stocks were recently subjected to insider selling. Juan Andres, the person in question, sold 5,000 MRNA shares this Monday, 29th March. The total transaction value was marked at $650,250 where the average selling price was $130.05 per stock.
MRNA stocks traded at $4.93 this Tuesday. The company’s current market capitalization stands at $47.46 billion. It has a negative PE ratio of 73.56 along with a beta of 1.73 at the moment. The current ratio is 2.43, the quick ratio at 2.43, and the debt-to-equity ratio at 0.04. The 12-monthly high to low ranges from $189.26 to $28.27. The 50SMA (Simple Moving Average) stands at $152.45 and its 200SMA stands at $117.27.
NASDAQ: MRNA Detailed Stock Analysis
The quarterly earnings report for the previous fiscal quarter was released by the company on the 25th of February. The earnings stood at $0.69 EPS for that quarter as opposed to the general consensus on the estimated earnings of $0.25 proposed by analysts at several research firms. The company’s return on equity currently stands at -28.11% along with a net margin of -242.73%.
The estimated income for the firm was marked at $279.41 million but it made $570.80 million for the quarter. Available data show that the company’s revenue increased by 3948.2% on a y-o-y basis. During the corresponding quarter previous year, the company posted an EPS of 0.37. Analysts expect the company to post Full Year 2020 earnings per share of -1.5.
NASDAQ: MRNA has recently been subject to a lot of reports by equities analysts. Some such as Barclays, SVB Leerink, Oppenheimer, Wells Fargo & Company, Morgan Stanley, and so on have posted reports on this firm over the last few months.
The recent consensus rating of Moderna, Inc. stands at “Hold” and the consensus on the target price is $150.56. Several hedge funds have also altered their shareholdings in the company recently.